{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 443274732
| IUPAC_name    = Methyl (naphthalen-2-yl)(piperidin-2-yl)acetate <!-- the locant ‘2’ for acetic acid is not cited -->
| image         = HDMP-28.png
| width         = 220
<!--Clinical data-->
| tradename                =
| routes_of_administration =
| legal_UK= Class B
| legal_UK_comment = [[Temporary Class Drug]]
<!--Identifiers-->
| index_label = 
| index2_label =
| CAS_number_Ref = {{cascite|changed|CAS}}
| CAS_number = 231299-82-4
| CAS_supplemental = <br />{{CAS|219915-69-2}} (HCl)
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = T52Y9T2U0W
| ATC_suffix     =
| PubChem        = 9817261
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID   = 7993011
| smiles2         = O=C(OC)[C@H](c2cc1ccccc1cc2)[C@@H]3NCCCC3
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI       = 1S/C18H21NO2/c1-21-18(20)17(16-8-4-5-11-19-16)15-10-9-13-6-2-3-7-14(13)12-15/h2-3,6-7,9-10,12,16-17,19H,4-5,8,11H2,1H3/t16-,17-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey    = DNRNSIJBSCBESJ-IAGOWNOFSA-N
<!--Chemical data-->
| C=18 | H=21 | N=1 | O=2
| molecular_weight = 283.365
| smiles = O=C(OC)[C@H](C1=CC2=C(C=C1)C=CC=C2)[C@]3([H])CCCCN3
}}

'''HDMP-28''' or '''methylnaphthidate''' is a [[piperidine]] based [[stimulant]] drug, closely related to [[methylphenidate]], but with the [[benzene]] ring replaced by [[naphthalene]]. It is a potent [[dopamine reuptake inhibitor]], with several times the potency of methylphenidate and a short duration of action,<ref>Lile JA, Wang Z, Woolverton WL, France JE, Gregg TC, Davies HM, Nader MA. The reinforcing efficacy of psychostimulants in rhesus monkeys: the role of pharmacokinetics and pharmacodynamics. ''Journal of Pharmacology and Experimental Therapeutics''. 2003 Oct;307(1):356-66. {{PMID|12954808}}</ref> and is a [[structural isomer]] of another potent dopamine reuptake inhibitor, [[N,O-Dimethyl-4-(2-naphthyl)piperidine-3-carboxylate]].
[[File:HDMP28andCFT-3D-overlay.png|thumb|HDMP-28 and CFT overlay]]
[[File:MMNPC&HDMP-28.png|200px]]

Most of the TMP analogs of HDMP-28 have [[serotonin transporter|SERT]] Ki values in the range >10,000 and so are selective for dopamine and noradrenaline reuptake, with little or no effect on serotonin. HDMP-28 also has high affinity to SERT, and so behaves as a [[triple reuptake inhibitor]].<ref>Davies HM, Hopper DW, Hansen T, Liu Q, Childers SR. Synthesis of methylphenidate analogues and their binding affinities at dopamine and serotonin transport sites. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1799-802. {{DOI|10.1016/j.bmcl.2003.12.097}} {{PMID|15026075}}</ref>

{| class="wikitable"
|+ <sup>a</sup>Effect of [[List of methylphenidate analogues|(dl-'''''threo''''') TMP and analogs]] on DA and 5HT Transporters.
|-
| colspan=7|Inhibition of specific analogs at displacing CFT from binding to DAT & RTI-55 from binding to SERT
|-
! Ar
! [<sup>3</sup>H][[WIN 35428|CFT]] DAT
! [<sup>3</sup>H]DA Uptake
! [<sup>3</sup>H][[RTI-55]] SERT
! Inhibition by 10μM
! D.R.
! Potency
|-
| [[Methylphenidate|Ph]] || 83.9 || 224 || >>10,000 || 19.6 || 2.7 || 1.00
|-
| [[4-Fluoromethylphenidate|''p''-F]] || 35.0 || 142 || >10,000 || 36.9 || 4.1 || 3.33
|-
| ''m''-Cl || 5.1 || 23.0 || >10,000 || 45.5 || 4.5 || 2.42
|-
| [[4-Methylmethylphenidate|''p''-Me]] || 33.0 || 126 || >10,000 || 45.0 || 3.8 || 0.74
|-
| ''p''-NH<sub>2</sub> || 34.5 || 114 || >>10,000 || 7.9 || 3.3 || 2.18
|-
| [[3,4-Dichloromethylphenidate|m,p-Cl<sub>2]]</sub> || 5.3 (2.67)<sup>b</sup> || 7.0 || 1,064 (>10,000)<sup>b</sup> || 93.3 || 1.3 || 7.98
|-
| β-Naphthyl || 33.9<sup>b</sup> 11.0<sup>c</sup> || 53.0<sup>c</sup> || 71.6<sup>b</sup> || nd || 4.8<sup>c</sup> || —
|-
| [[Cocaine]] || 160 || 404 || 401 || nd || 2.5 || 0.41
|- bgcolor="lightgray"
| colspan = 7 | <sup>a</sup>Schweri, et al. (2002);<ref>Schweri MM, Deutsch HM, Massey AT, Holtzman SG. Biochemical and behavioral characterization of novel methylphenidate analogs. J Pharmacol Exp Ther. 2002 May;301(2):527-35. {{DOI|10.1124/jpet.301.2.527}} {{PMID|11961053}}</ref> <sup>b</sup>Davies, et al. (2004);<ref>Davies HM, Hopper DW, Hansen T, Liu Q, Childers SR. Synthesis of methylphenidate analogues and their binding affinities at dopamine and serotonin transport sites. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1799-802. {{DOI|10.1016/j.bmcl.2003.12.097}} {{PMID|15026075}}</ref> <sup>c</sup>Deutsch, et al. (2001).<ref>Deutsch HM, Ye X, Shi Q, Liu Z, Schweri MM. Synthesis and pharmacology of site specific cocaine abuse treatment agents: a new synthetic methodology for methylphenidate analogs based on the Blaise reaction. Eur J Med Chem. 2001 Apr;36(4):303-11. {{PMID|11461755}}</ref>
|}

<small>D.R. = Discrimination Ratio = [3H]DA ÷ [3H]CFT.

A low D.R. = addictive, whereas a high D.R. = low propensity for self-administration.</small>

== Legality ==

HDMP-28 is illegal in Switzerland as of December 2015.<ref>{{cite web | url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html | title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien | publisher=Der Bundesrat}}</ref>

== See also ==
* [[3,4-Dichloromethylphenidate]]
* [[Ethylphenidate]]
* [[HDEP-28]]
* [[Naphthylisopropylamine]]
* [[Naphyrone]]
* [[2β-Propanoyl-3β-(2-naphthyl)-tropane]] (WF-23)
* [[Isopropylphenidate]]
* [[Propylphenidate]]

== References ==
{{Reflist|2}}

{{Stimulants}}
{{Monoamine reuptake inhibitors}}

[[Category:Piperidines]]
[[Category:Dopamine reuptake inhibitors]]
[[Category:Stimulants]]
[[Category:Designer drugs]]
[[Category:Naphthalenes]]